Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
Phio Pharmaceuticals (NASDAQ: PHIO) reported Q2 2026 results for the quarter ended June 30, 2026 and updated its PH-762 siRNA program. Cash fell to $13.0M from $21.0M at Dec. 31, 2025. R&D rose to $3.1M and net loss widened to $4.1M. PH-762 Phase 1b (22 patients) completed in March; FDA documentation is being prepared and an FDA meeting is planned for Q3 2026. The company also launched a $6.36M ATM equity program.
How this was made
The 30-second read
Why it matters
The update combines (1) PH-762 development execution milestones, (2) a planned FDA interaction in 3Q26, (3) multiple favorable patent actions, and (4) financials showing higher burn and a reduced cash balance, alongside an ATM equity program for capital sourcing.
Market read
Traders can reassess PH-762 de-risking progress and the near-term regulatory pathway, while also pricing dilution and burn-rate risk from the ATM and rising R&D costs.
What to watch
Cash fell to $13.0M from $21.0M at year-end, and R&D is rising sharply, so investors may focus on burn rate and dilution timing rather than Phase 1b documentation progress.
Background
Phio is a clinical-stage siRNA biopharmaceutical using INTASYL gene silencing, with PH-762 targeting PD-1 in skin cancers via intratumoral dosing.
Ticker impact
Phio reported 2Q26 results and said it started commercial-scale PH-762 API, dosed a long-term nonclinical tox study, and is preparing FDA submission materials.
Moderate upside bias if investors view the operational milestones and FDA pathway as de-risking, but dilution risk from the ATM program can cap rallies.
The release adds concrete development progress (API scale-up, tox dosing, Phase 1b documentation) plus a stated cash runway into 2H27, but it also discloses an ATM equity program that can pressure the stock.
Market effects
Reinforces siRNA oncology platform execution expectations, but does not introduce new sector-wide regulatory or trial read-through beyond PH-762.
Limited direct regional impact; primarily US biotech investor sentiment.
Global IP updates (US, Canada, Japan) may modestly support broader confidence in INTASYL IP defensibility.
Counterpoint
Operational milestones may not translate into clinical efficacy or FDA acceptance; the ATM program signals ongoing funding needs that can dilute per-share value.
Key entities
- companyPhio Pharmaceuticals Corp.
NASDAQ-listed clinical-stage siRNA company reporting 2Q26 financial results and PH-762 business updates.
- programPH-762
Lead INTASYL siRNA candidate evaluated in a Phase 1b intratumoral dose-escalation trial for skin cancers.
- financial_agentH.C. Wainwright & Co., LLC
Sales agent for Phio’s at-the-market (ATM) equity offering program.
- regulatorFDA
Phio intends to request an FDA meeting in 3Q26 to discuss next clinical trial design steps.
